Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune checkpoint inhibitor plus apatinib and XELOX for first-line recurrent or metastatic gastric cancer
ChiCTR2400084310Phase 2Recruiting
- Sponsor
- Dengzhou People's Hospital
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib, oxaliplatin and capecitabine in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Dengzhou People's Hospital. Primary endpoint: Progression-free survival. Started May 2024; status: recruiting.
02
Drugs
Rivoceraniboxaliplatincapecitabine
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400084310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084310.